02:26 PM EDT, 03/11/2024 (MT Newswires) -- Moderna ( MRNA ) and Merck ( MRK ) will start a phase 2/3 study of cancer vaccine V940, or mRNA-4157, plus pembrolizumab in patients with cutaneous squamous cell carcinoma, a form of skin cancer, according to a government trial website.

The study is expected to begin on April 18, according to ClinicalTrials.gov.

Price: 112.39, Change: +9.36, Percent Change: +9.08